ClinicalTrials.gg

Program

pirtobrutinib

Also written as “Pirtobrutinib”, “LOXO-305” and “[14C]-LOXO-305”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Mantle-Cell · Renal Insufficiency, led by 3 companies.

Furthest: phase 4, since Mar 6, 202530 company-led studies, 12 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly2811 open or runningphase 4since Mar 6, 2025Nov 6, 2018Oct 2027phase 3 · NCT05254743
AstraZeneca10 open or runningphase 2since Jan 21, 2025Jan 21, 2025none ahead
Nurix Therapeutics11 open or runningphase 3since Mar 31, 2026Mar 31, 2026Oct 2029phase 3 · NCT07516093

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Nov 6, 2018.

  1. Oct 22, 20212 phase 1 studies in Healthy VolunteersEli Lilly · NCT05134350, NCT05134337
  2. Jan 3, 2022Phase 1 study in HealthyEli Lilly · NCT05176314 · 32 enrolled · United States
  3. Feb 15, 2022Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT05254743 · 737 planned · United States, Argentina, Australia and more
  4. Oct 24, 2023Phase 2 study in Multiple SclerosisEli Lilly · NCT06104683 · United States, Puerto Rico
  5. Nov 30, 2023Phase 1 study in HealthyEli Lilly · NCT06165146 · 16 enrolled · United States
  6. Dec 11, 20239 phase 1 studiesEli Lilly · NCT06190691, NCT06190678, NCT06194214 and 6 more
  7. Feb 6, 2024Phase 1 study in HealthyEli Lilly · NCT06258174 · 28 enrolled · United States
  8. Sep 6, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT06588478 · 249 planned · United States, Australia, Belgium and more
  9. Dec 3, 2024Phase 2 study in Purpura, Thrombocytopenic, IdiopathicEli Lilly · NCT06721013 · 68 planned · United States, China, Denmark and more
  10. Jan 21, 2025AstraZeneca's first study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to AstraZenecaAstraZeneca · NCT06839872
  11. Mar 6, 20252 phase 4 studies in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT06876662, NCT06876649
  12. Aug 29, 2025Phase 2 study in Lymphoma, Non-HodgkinEli Lilly · NCT07162181 · 13 enrolled · China
  13. Oct 16, 2025Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT07218341 · 150 planned · United States, Australia, Austria and more
  14. Mar 31, 2026Nurix Therapeutics's first study: phase 3 study in Lymphoma, B-CellNew to Nurix TherapeuticsNurix Therapeutics · NCT07516093 · 620 planned · United States

Ahead

  1. Oct 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT05254743
  2. Nov 2027Primary completion: phase 3 study in Lymphoma, Mantle-CellEli Lilly · NCT04662255
  3. Feb 2028Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicEli Lilly · NCT06721013
  4. Jun 2028Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT06588478

TargetBeta

BTK →read by rule
“An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07516093Lymphoma, B-Cell · United States3RecruitingNurix TherapeuticsOct 2029620
NCT07218341Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more4RecruitingEli LillyMay 2030150
NCT07162181Lymphoma, Non-Hodgkin · China2Active, not recruitingEli LillyMay 203013
NCT06876662Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more4RecruitingEli LillyMay 2030279
NCT06876649Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more4RecruitingEli LillyMay 2030787
NCT06839872Leukemia, Lymphocytic, Chronic, B-Cell2WithdrawnAstraZenecaJul 28, 20280
NCT06721013Purpura, Thrombocytopenic, Idiopathic · United States, China, Denmark and more2RecruitingEli LillyFeb 202868
NCT06588478Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more2RecruitingEli LillyJun 2028249
NCT06258174Healthy · United States1CompletedEli LillyDec 22, 202128
NCT06215521Healthy · United States1CompletedEli LillyMar 31, 202131
NCT06215430Healthy · United States1CompletedEli LillyApr 15, 202116
NCT06194214Healthy · United States1CompletedEli LillyJun 9, 202116
NCT06181006Healthy · United States1CompletedEli LillyDec 1, 202024
NCT06180980Healthy · United States1CompletedEli LillyMar 8, 202120
NCT06180967Healthy · United States1CompletedEli LillyOct 20, 202015
NCT06180954Healthy · United States1CompletedEli LillyNov 6, 20209
NCT06190691Hepatic Insufficiency · United States1CompletedEli LillyDec 30, 202136
NCT06190678Renal Insufficiency · United States1CompletedEli LillyJun 4, 202116
NCT06165146Healthy · United States1CompletedEli LillyDec 30, 202016
NCT06104683Multiple Sclerosis · United States, Puerto Rico2WithdrawnEli LillyJan 16, 20260
NCT05254743Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3RecruitingEli LillyOct 2027737
NCT05176314Healthy · United States1CompletedEli LillyApr 20, 202232
NCT05134350Healthy Volunteers · United States1CompletedEli LillyMar 23, 202010
NCT05134337Healthy Volunteers · United States1CompletedEli LillyOct 30, 202027
NCT05023980Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingEli LillyJul 11, 2025282
NCT04965493Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3Active, not recruitingEli LillyOct 2026600
NCT04849416Leukemia, Lymphoid · China2CompletedEli LillyApr 10, 202387
NCT04666038Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingEli LillyAug 29, 2023238
NCT04662255Lymphoma, Mantle-Cell · United States, Australia, Austria and more3Active, not recruitingEli LillyNov 2027500
NCT03740529Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more2CompletedEli LillyJan 27, 2025803

How it is read

Names in the registry

  • “Pirtobrutinib”, 26 entries
  • “LOXO-305”, 3 entries
  • “[14C]-LOXO-305”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.